Credit and interest ratesnegative · 5 filings
“58 Table of Contents ImmunityBio, Inc.”10-Q · Aug 4, 2026 ↗
ImmunityBio, Inc.
IBRX
Market read
ImmunityBio, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.
Company-4.4% todayVolume comparison unavailable
Market group0 of 37 activeBiotechnology · unavailable
Disclosed network0 of 7 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- Management says continuing operating cash outflows create substantial doubt about going concern without additional funding or financial support.
Invalidation: The isolated read changes if IBRX's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- Management says continuing operating cash outflows create substantial doubt about going concern without additional funding or financial support.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations327
Usable filing statements105
Verified relationships7
Evidence supporting the case
- Latest annual revenue changed +668.3% year over year.
- Operating margin changed +2108.2 percentage points in the latest annual period.
- Net margin changed +2494.6 percentage points in the latest annual period.
Evidence challenging the case
- Diluted shares increased 31.3% in the latest annual period.
- Credit and interest rates has repeated adverse evidence across 5 filings.
Questions before a position
- EV/sales is 40% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 10, 2026
7.736m-6.6%12m+200.6%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$934,000+54.4%$-0.89+3.2%
2022-12-31$240,000-74.3%$-1.04+2.7%
2023-12-31$622,000+159.2%$-1.15+27.2%
2024-12-31$14.7M+2270.6%$-0.62+37.7%
2025-12-31$113.3M+668.3%$-0.38+31.3%
What management says matters
Persistent and emerging business drivers
Legal and regulatory exposuremixed · 4 filings
“In addition, subject to obtaining regulatory approval of our other product candidates, we expect to incur significant incremental commercialization expenses for product sales, marketing, manufacturing and distribution.”10-Q · May 7, 2026 ↗
Tariffs and trade policypositive · 2 filings
“While certain products were excluded from some of these reciprocal tariff measures, including items subject to Section 232 tariffs; certain pharmaceuticals and pharmaceutical products; and certain semiconductors, computers, consumer electronics, and other pro…”10-Q · Nov 5, 2025 ↗
Foreign exchangemixed · 1 filings
“Changes in fair value of contingent consideration were immaterial during the years ended December 31, 2025 , 2024 and 2023, and were primarily due to changes in foreign currency exchange rates.”10-K · Feb 23, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 62.7× · EV/sales 61.9×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
7.73-4.4% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for IBRX. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for IBRX. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind IBRX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
URGNUroGen Pharma Ltd.competitorMar 2, 2026 ▾
“We are aware of several pharmaceutical companies that are developing drugs in the general fields of urology and uro-oncology, such as AstraZeneca, Aura Biosciences., Bristol Myers Squibb, CG Oncology, enGene Holdings, Ferring Pharmaceuticals, Fidia Pharmaceut…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
IBRX is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for IBRX; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.